Business / Finance

RSS

Creekridge Capital reports record-breaking volume for first quarter 2011

Creekridge Capital LLC, a nationwide independent healthcare and technology vendor leasing company, announced record-breaking volume for first quarter 2011 that exceeds any previous first quarter volume throughout its history.

8 Apr 2011

The MED Group creates National Orthotics and Prosthetics Network

The MED Group, a Managed Health Care Associates, Inc. (MHA) company, and a leading group purchasing and business solutions company focused on Home Medical Equipment providers is pleased to announce the creation of The MED Group National Orthotics and Prosthetics Network. Tim Pederson (formerly of WestMed Rehab) has joined The MED Group and will be leading the development of The MED Group's National Orthotics & Prosthetics Network.

8 Apr 2011

Sangamo prices public offering of 6.7M shares of common stock

Sangamo BioSciences, Inc. today announced the pricing of its previously announced public offering of 6,700,000 shares of its common stock at a price to the public of $7.70 per share. The public offering is expected to close on or around Wednesday, April 13, 2011, subject to customary closing conditions.

8 Apr 2011

Novation adds St. Jude Medical to portfolio of Cardiac Rhythm Management products

Novation, the leading health care supply contracting company, announced today the addition of St. Jude Medical (St. Paul, MN) to its portfolio of agreements for Cardiac Rhythm Management products.

8 Apr 2011

HCP closes acquisition of HCR ManorCare facilities for $6.1 billion

HCP announced that it closed the acquisition of 334 post-acute, skilled nursing and assisted living facilities of HCR ManorCare for a total consideration of $6.1 billion in cash. In connection with the closing, HCP entered into a long-term triple-net master lease under which HCR ManorCare will continue to operate the facilities.

8 Apr 2011

Amgen acquires Bergamo, expands operations in Brazil

Amgen, the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company.

8 Apr 2011

Impax, Banner Pharmacaps collaborate for commercialization of softgel capsule products

Impax Laboratories, Inc. today announced that it will collaborate with Banner Pharmacaps Inc. with respect to the supply and commercialization of two softgel capsule products.

8 Apr 2011

Idenix prices underwritten registered public offering of 18 million shares of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.

8 Apr 2011

Idenix begins underwritten registered public offering of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of shares of its common stock. All of these shares are being sold by Idenix.

8 Apr 2011

Catalyst Health prices public offering of 5,500,000 shares of common stock

Catalyst Health Solutions, Inc. today announced the successful pricing of its public offering of 5,500,000 shares of common stock, consisting of 4,500,000 shares to be sold by the Company and 1,000,000 shares to be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., at a price of $53.00 per share.

8 Apr 2011

Alcon to merge with Novartis at its Annual General Meeting of Shareholders

Alcon, Inc. announced that its shareholders approved the merger of Alcon into Novartis AG at its Annual General Meeting of Shareholders.

8 Apr 2011

Rochester Medical acquires Laprolan

Rochester Medical Corporation today announced that it has now completed the previously announced purchase of Laprolan B.V., the former Medical Supplies Division and wholly owned subsidiary of Fornix BioSciences N.V. Under the terms of the purchase agreement the purchase is deemed retroactive to January 1, 2011.

8 Apr 2011

Rite Aid reports fourth quarter net loss of $205.7 million

Rite Aid Corporation today reported financial results for the fourth quarter and fiscal year ended February 26, 2011.

7 Apr 2011

Gerresheimer first quarter group revenues increase 5.2% to EUR 236.6m

Gerresheimer AG, one of the leading global suppliers to the pharma and healthcare industry, got off to a good start in the new financial year. "We continued on our successful course in the new financial year.

7 Apr 2011

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court.

7 Apr 2011

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has acquired assets relating to the vaccine HibTITER from Wyeth LLC, a wholly owned subsidiary of Pfizer Inc, for the U.S. and many other markets, including Japan and Korea. Financial terms of the sale were not disclosed.

7 Apr 2011

LabCorp to acquire Orchid Cellmark

Laboratory Corporation of America® Holdings and Orchid Cellmark Inc., an international provider of DNA testing services primarily for forensic and family relationship applications, today announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Orchid Cellmark in a cash tender offer for $2.80 per share for a total purchase price to stockholders and optionholders of approximately $85.4 million.

6 Apr 2011

Ascletis raises $100 million in committed financing

Ascletis, Inc., a U.S.-China specialty life sciences venture focused on cancer and infectious disease therapeutics, today announced the company's formation and completion of a Series A private equity financing. Ascletis has raised US$100 million in committed financing including a first tranche of US$50 million. The investors, led by Hangzhou Binjiang Investment Holding Co., Ltd., included private entrepreneurs from China and other countries including the United States.

6 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Nu Skin first-quarter revenue increases 9% to $395 million

Nu Skin Enterprises, Inc. today announced that it expects to exceed previous company guidance by posting first-quarter revenue of approximately $395 million, a 9 percent improvement over the prior-year period. Revenue is expected to benefit approximately 5 percent due to foreign currency fluctuations.

6 Apr 2011